title: Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib.
authors.affiliation: Universitair Ziekenhuis Brussel, Brussels, Belgium.
authors.forename: Sofie
authors.initials: S
authors.lastname: Wilgenhof
authors.affiliation: Universitair Ziekenhuis Brussel, Brussels, Belgium Bart.Neyns@uzbrussel.be.
authors.forename: Bart
authors.initials: B
authors.lastname: Neyns
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D057176:Compassionate Use Trials; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008545:Melanoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000556:secondary; D055756:Meningeal Carcinomatosis / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000556:secondary; D008875:Middle Aged; D009154:Mutation; D010091:Oximes / Q000627:therapeutic use*; D010641:Phenotype; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics; D012074:Remission Induction; D012878:Skin Neoplasms / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D010091:Oximes; D047428:Protein Kinase Inhibitors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib